## Nereo Segnan, Epi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4660243/publications.pdf

Version: 2024-02-01

70961 46693 8,066 97 41 89 citations h-index g-index papers 99 99 99 7002 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet, The, 2014, 383, 524-532.	6.3	1,282
2	Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncology, The, 2010, 11, 249-257.	5.1	797
3	Once-Only Sigmoidoscopy in Colorectal Cancer Screening: Follow-up Findings of the Italian Randomized Controlled TrialSCORE. Journal of the National Cancer Institute, 2011, 103, 1310-1322.	3.0	539
4	ADJUSTING FOR NON-COMPLIANCE AND CONTAMINATION IN RANDOMIZED CLINICAL TRIALS. Statistics in Medicine, 1997, 16, 1017-1029.	0.8	277
5	Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled Trial. Journal of the National Cancer Institute, 2006, 98, 765-774.	3.0	275
6	Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. Journal of the National Cancer Institute, 2008, 100, 492-501.	3.0	259
7	Comparing Attendance and Detection Rate of Colonoscopy With Sigmoidoscopy and FIT for Colorectal Cancer Screening. Gastroenterology, 2007, 132, 2304-2312.	0.6	241
8	Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ: British Medical Journal, 2007, 335, 28.	2.4	224
9	Baseline Findings of the Italian Multicenter Randomized Controlled Trial of "Once-Only Sigmoidoscopy"SCORE. Journal of the National Cancer Institute, 2002, 94, 1763-1772.	3.0	206
10	Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncology, The, 2006, 7, 547-555.	5.1	202
11	European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Papillomavirus Research (Amsterdam, Netherlands), 2015, 1, 22-31.	4.5	181
12	Randomized Trial of Different Screening Strategies for Colorectal Cancer: Patient Response and Detection Rates. Journal of the National Cancer Institute, 2005, 97, 347-357.	3.0	178
13	European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk. Cancer Epidemiology, 2015, 39, S1-S10.	0.8	176
14	Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomised controlled trial. Lancet Oncology, The, 2008, 9, 937-945.	5.1	170
15	Breast Cancer Mortality in Mammographic Screening in Europe: A Review of Incidence-Based Mortality Studies. Journal of Medical Screening, 2012, 19, 33-41.	1.1	152
16	Mammographic Screening Programmes in Europe: Organization, Coverage and Participation. Journal of Medical Screening, 2012, 19, 72-82.	1.1	142
17	Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncology, The, 2013, 14, 168-176.	5.1	139
18	Exposure of nonsmoking women to environmental tobacco smoke: a 10-country collaborative study. Cancer Causes and Control, 1990, 1, 243-252.	0.8	127

#	Article	IF	Citations
19	Performance of colorectal cancer screening in the European Union Member States: data from the second European screening report. Gut, 2019, 68, 1232-1244.	6.1	113
20	High Rate of Advanced Adenoma Detection in 4 Rounds of Colorectal Cancer Screening With the Fecal Immunochemical Test. Clinical Gastroenterology and Hepatology, 2012, 10, 633-638.	2.4	103
21	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. European Journal of Cancer, 2020, 127, 224-235.	1.3	101
22	Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ: British Medical Journal, 2017, 356, i6673.	2.4	100
23	Prevalence of human papillomavirus infection in women in Turin, Italy. European Journal of Cancer, 2005, 41, 297-305.	1.3	94
24	Optimising colorectal cancer screening acceptance: a review. Gut, 2015, 64, 1158-1177.	6.1	92
25	Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A service screening study in Italy. Breast Cancer Research, 2006, 8, R68.	2.2	79
26	A randomized trial of smoking cessation interventions in general practice in Italy. Cancer Causes and Control, 1991, 2, 239-246.	0.8	77
27	Acceptability and side-effects of colonoscopy and sigmoidoscopy in a screening setting. Journal of Medical Screening, 2011, 18, 128-134.	1.1	73
28	A high positive predictive value algorithm using hospital administrative data identified incident cancer cases. Journal of Clinical Epidemiology, 2008, 61, 373-379.	2.4	71
29	HPV triage for low grade (L-SIL) cytology is appropriate for women over 35 in mass cervical cancer screening using liquid based cytology. European Journal of Cancer, 2007, 43, 476-480.	1.3	65
30	Comparing Different Strategies for Colorectal Cancer Screening in Italy: Predictors of Patients' Participation. American Journal of Gastroenterology, 2010, 105, 188-198.	0.2	64
31	European Code against Cancer, 4th Edition: Cancer screening. Cancer Epidemiology, 2015, 39, S139-S152.	0.8	64
32	Predictors of Smoking Cessation Following Physician' Counseling. Preventive Medicine, 1998, 27, 412-421.	1.6	61
33	Informed Cytology for Triaging HPV-Positive Women: Substudy Nested in the NTCC Randomized Controlled Trial. Journal of the National Cancer Institute, 2015, 107, .	3.0	61
34	Full-spectrum (FUSE) versus standard forward-viewing colonoscopy in an organised colorectal cancer screening programme. Gut, 2017, 66, gutjnl-2016-311906.	6.1	59
35	Determinants of successful implementation of population-based cancer screening programmes. European Journal of Cancer, 2012, 48, 743-748.	1.3	56
36	Inter-observer and intra-observer variability of mammogram interpretation: a field study. European Journal of Cancer, 1992, 28, 1054-1058.	1.3	53

#	Article	IF	Citations
37	Offering people a choice for colorectal cancer screening. Gut, 2013, 62, 735-740.	6.1	50
38	Population Based Cancer Screening Programmes as a Teachable Moment for Primary Prevention Interventions. A Review of the Literature. Frontiers in Oncology, 2012, 2, 45.	1.3	48
39	Screening for Colorectal Cancer by Once Only Sigmoidoscopy: A Feasibility Study in Turin, Italy. Journal of Medical Screening, 1996, 3, 72-78.	1.1	44
40	What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. European Journal of Cancer, 2009, 45, 2714-2721.	1.3	44
41	Early diagnosis, not differential treatment, explains better survival in service screening. European Journal of Cancer, 2005, 41, 2728-2734.	1.3	42
42	Sun exposure prior to diagnosis is associated with improved survival in melanoma patients: Results from a long-term follow-up study of Italian patients. European Journal of Cancer, 2008, 44, 1275-1281.	1.3	42
43	Accessibility as a major determinant of radiotherapy underutilization: A population based study. Health Policy, 2007, 80, 483-491.	1.4	41
44	Who Has Pap Tests?: Variables Associated with the Use of Pap Tests in Absence of Screening Programmes. International Journal of Epidemiology, 1991, 20, 349-353.	0.9	40
45	International variation in management of screen-detected ductal carcinoma in situ of the breast. European Journal of Cancer, 2014, 50, 2695-2704.	1.3	32
46	HPV testing for primary cervical cancer screening. Lancet, The, 2007, 370, 1740-1742.	6.3	28
47	HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions. Epidemics, 2010, 2, 21-28.	1.5	27
48	Re: Breast Cancer Incidence, 1980-2006: Combined Roles of Menopausal Hormone Therapy, Screening Mammography, and Estrogen Receptor Status. Journal of the National Cancer Institute, 2007, 99, 1817-1818.	3.0	26
49	Invitation strategies for colorectal cancer screening programmes: The impact of an advance notification letter. Preventive Medicine, 2015, 73, 106-111.	1.6	26
50	Comparing CT colonography and flexible sigmoidoscopy: a randomised trial within a population-based screening programme. Gut, 2017, 66, 1434-1440.	6.1	26
51	Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial. Annals of Internal Medicine, 2022, 175, 36-45.	2.0	25
52	Modelling patterns of clearance of HPV-16 infection and vaccination efficacy. Vaccine, 2011, 29, 1270-1277.	1.7	24
53	Improving the quality of communication in organised cervical cancer screening programmes. Patient Education and Counseling, 2008, 72, 130-136.	1.0	23
54	Compliance with clinical practice guidelines for breast cancer treatment: a population-based study of quality-of-care indicators in Italy. BMC Health Services Research, 2013, 13, 28.	0.9	23

#	Article	IF	CITATIONS
55	European Code against Cancer 4th Edition: Process of reviewing the scientific evidence and revising the recommendations. Cancer Epidemiology, 2015, 39, S11-S19.	0.8	23
56	Population screening for colorectal cancer by flexible sigmoidoscopy or CT colonography: study protocol for a multicenter randomized trial. Trials, 2014, 15, 97.	0.7	22
57	The EUROMED CANCER network: state-of-art of cancer screening programmes in non-EU Mediterranean countries. European Journal of Public Health, 2016, 26, 83-89.	0.1	21
58	Ascertainment and evaluation of interval cancers in population-based mammography screening programmes: a collaborative study in four European centres. Journal of Medical Screening, 2005, 12, 43-49.	1.1	20
59	Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. Journal of Clinical Virology, 2006, 36, 126-132.	1.6	19
60	Virtual microscopy for histology quality assurance of screen-detected polyps. Journal of Clinical Pathology, 2010, 63, 916-920.	1.0	19
61	Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC trial. BMC Infectious Diseases, 2013, 13, 238.	1.3	19
62	CT Colonography: Preliminary Assessment of a Double-Read Paradigm That Uses Computer-aided Detection as the First Reader. Radiology, 2013, 268, 743-751.	3.6	19
63	Computer-Aided Detection for Computed Tomographic Colonography Screening. Investigative Radiology, 2014, 49, 173-182.	3 <b>.</b> 5	19
64	Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test. Journal of Medical Screening, 2019, 26, 76-83.	1.1	19
65	Predicting Proximal Advanced Neoplasms at Screening Sigmoidoscopy. Diseases of the Colon and Rectum, 2004, 47, 1331-1340.	0.7	17
66	The New Technologies for Cervical Cancer Screening randomised controlled trial. An overview of results during the first phase of recruitment. Gynecologic Oncology, 2007, 107, S230-S232.	0.6	17
67	Flexible Sigmoidoscopy and CT Colonography Screening: Patients' Experience with and Factors for Undergoing Screening—Insight from the Proteus Colon Trial. Radiology, 2018, 286, 873-883.	3 <b>.</b> 6	17
68	The impact of different communication and organizational strategies on mammography screening uptake in women aged 40-45 years. European Journal of Public Health, 2012, 22, 413-418.	0.1	16
69	Lifetime growth and risk of testicular cancer. International Journal of Cancer, 2014, 135, 695-701.	2.3	16
70	Colorectal cancer screening of immigrants to Italy. Figures from the 2013 National Survey. Preventive Medicine, 2015, 81, 132-137.	1.6	16
71	Narrow band imaging vs. high definition colonoscopy for detection of colorectal adenomas in patients with positive faecal occult blood test: A randomised trial. Digestive and Liver Disease, 2014, 46, 803-807.	0.4	14
72	Epidemiologic evidence of slow growing, nonprogressive or regressive breast cancer: A systematic review. International Journal of Cancer, 2016, 139, 554-573.	2.3	14

#	Article	IF	CITATIONS
73	What information do breast cancer screening programmes provide to Italian women?. European Journal of Public Health, 2005, 15, 66-69.	0.1	13
74	Impact of the AutoPap (currently focalpoint) primary screening system location guide use on interpretation time and diagnosis. Cancer, 2002, 99, 83-88.	2.0	12
75	Genetic polymorphisms of CYP17A1, vitamin D receptor and androgen receptor in Italian heredo-familial and sporadic prostate cancers. Cancer Epidemiology, 2011, 35, e18-e24.	0.8	12
76	HPV Testing Is an Efficient Management Choice for Women With Inadequate Liquid-Based Cytology in Cervical Cancer Screening. American Journal of Clinical Pathology, 2012, 138, 65-71.	0.4	11
77	The impact of new technologies in cervical cancer screening: Results of the recruitment phase of a large randomised controlled trial from a public health perspective. International Journal of Cancer, 2007, 121, 2729-2734.	2.3	10
78	Evaluation of service mammography screening impact in Italy. The contribution of hazard analysis. European Journal of Cancer, 2008, 44, 858-865.	1.3	10
79	A comparison of different strategies used to invite subjects with a positive faecal occult blood test to a colonoscopy assessment. A randomised controlled trial in population-based screening programmes. Preventive Medicine, 2014, 65, 70-76.	1.6	10
80	HPV-based screening for prevention of invasive cervical cancer – Authors' reply. Lancet, The, 2014, 383, 1295.	6.3	10
81	Inequalities in cervical cancer screening utilisation and results: A comparison between Italian natives and immigrants from disadvantaged countries. Health Policy, 2017, 121, 1072-1078.	1.4	9
82	Cervical screening according to age and HPV status. BMJ: British Medical Journal, 2009, 339, b3005-b3005.	2.4	8
83	Distribution of colorectal polyps: Implications for screening. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 481-488.	1.0	8
84	Number of Adenomas Removed and Colorectal Cancers Prevented in Randomized Trials of Flexible Sigmoidoscopy Screening. Gastroenterology, 2018, 155, 1059-1068.e2.	0.6	8
85	History of negative colorectal endoscopy and risk of rectosigmoid neoplasms at screening flexible sigmoidoscopy. International Journal of Colorectal Disease, 2006, 21, 105-113.	1.0	7
86	HPV16 and HPV18 genotyping in cervical cancer screening. Lancet Oncology, The, 2011, 12, 831-832.	5.1	7
87	Histological features of advanced colorectal adenomas detected by endoscopy and fecal immunochemical test. Endoscopy, 2015, 47, 903-909.	1.0	7
88	Absence of socioeconomic inequalities in access to good-quality breast cancer treatment within a population-wide screening programme in Turin (Italy). European Journal of Cancer Prevention, 2016, 25, 538-546.	0.6	6
89	The differential diagnosis of primary lung cancer: Inter-observer agreement and contribution of specific diagnostic procedures. Journal of Clinical Epidemiology, 1992, 45, 827-833.	2.4	5
90	Early detection versus prevention in colorectal cancer screening: Methods estimates and public health implications. Cancer, 2017, 123, 4767-4769.	2.0	5

#	Article	IF	CITATIONS
91	Re: Role of Detection Method in Predicting Breast Cancer Survival: Analysis of Randomized Screening Trials. Journal of the National Cancer Institute, 2005, 97, 1853-1854.	3.0	4
92	Assessing Generalizability of the Findings of Sigmoidoscopy Screening Trials: The Case of SCORE Trial. Journal of the National Cancer Institute, 2015, 107, 385.	3.0	4
93	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. MDM Policy and Practice, 2021, 6, 238146832098497.	0.5	4
94	Is the Breast Cancer Mortality Decrease in Sweden Due to Screening or Treatment? Not the Right Question. Journal of the National Cancer Institute, 2012, 104, 1040-1041.	3.0	3
95	Efficacy of HPV-Based Screening for Prevention of Invasive Cervical Cancer. Obstetrical and Gynecological Survey, 2014, 69, 472-473.	0.2	1
96	Warunki skutecznej realizacji program $\tilde{A}^3$ w populacyjnych bada $\mathring{A}$ , przesiewowych w kierunku nowotwor $\tilde{A}^3$ w. Nowotwory, 2015, 64, 511-517.	0.1	1
97	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 379-380.	1.0	0